Find in Library

A preliminary study was carried out to evaluate the efficacy of intranasal canine parvovirus vaccination in pups. Six healthy unvaccinated pups of six to eight weeks of age with a maternal ntibody titre less than 1:80 were vaccinated intranasally with one drop of attenuated canine parvovirus type 2 (CPV-2) antigens, each dose containing 103TCIDG~antigenic mass on day zero and day two and seroconversion was assessed by HI test and SNT on day seven, 14, 28, 60 and 90 days post vaccination. All the pups were seroconverted and had protective titre against CPV within a week or two after vaccination. Results of the present study indicated that intranasal vaccination can be used as an effective, safe and non invasive route for canine parvovirus vaccination and a minimal vaccine volume was able to induce active immune responses in all pups